Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael DePaolis

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Contact Lens & Anterior Eye : the Journal of the British Contact Lens Association|January 26, 2013
5. What do we do now? Implications for the clinical practiceMichael DePaolis, Pauline Cho, Derek Cunningham, et al.
Clinical Therapeutics|April 28, 2009
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyPaul Karpecki, Michael Depaolis, Judy A Hunter, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Contact Lens & Anterior Eye : the Journal of the British Contact Lens Association|January 26, 2013
5. What do we do now? Implications for the clinical practiceMichael DePaolis, Pauline Cho, Derek Cunningham, et al.
Clinical Therapeutics|April 28, 2009
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyPaul Karpecki, Michael Depaolis, Judy A Hunter, et al.
Pageof 1